Immunisation of dairy cattle with recombinant Streptococcus uberis GapC or a chimeric CAMP antigen confers protection against heterologous bacterial challenge

Vaccine

Volumn 20, Issue 17-18, 2002, Pages 2278-2286

  Fontaine, Michael C ^a   Perez Casal, Jose ^a   Song, Xin Ming ^a   Shelford, Jim ^b   Willson, Philip J ^a   Potter, Andrew A ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

CAMP factor; GapC; Glyceraldehyde 3 phosphate dehydrogenase; Mastitis; Streptococcus uberis; Vaccine

Indexed keywords

CHIMERIC PROTEIN; PROTEIN CAMP 3; PROTEIN GAPC; RECOMBINANT PROTEIN; STREPTOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN DETECTION; ARTICLE; BACTERIAL COUNT; CATTLE DISEASE; CONTROLLED STUDY; DAIRY CATTLE; DISEASE SEVERITY; EXPERIMENTAL INFECTION; FEMALE; GENE SEQUENCE; GENETIC CODE; IMMUNIZATION; INFLAMMATION; LACTATION; MILK; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROVOCATION TEST; SOMATIC CELL; SPECIES DIFFERENCE; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS UBERIS; VACCINATION;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BASE SEQUENCE; CATTLE; CLONING, MOLECULAR; DNA, BACTERIAL; FEMALE; GENE EXPRESSION; GENES, BACTERIAL; HEMOLYSIN PROTEINS; MASTITIS, BOVINE; MOLECULAR SEQUENCE DATA; RECOMBINANT PROTEINS; RECOMBINATION, GENETIC; STREPTOCOCCAL VACCINES; STREPTOCOCCUS; VACCINATION; VACCINES, SYNTHETIC;

EID: 0037157231     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00114-7     Document Type: Article

References (30)

1. The costs of production diseases in dairy herds in England
2. Sources of Streptococcus uberis in the dairy herd. I. Isolation from bovine faeces and from straw bedding of cattle
3. Sources of Streptococcus uberis in the dairy herd. II. Evidence of colonization of the bovine intestine by Streptococcus uberis
4. Field survey of clinical mastitis in low somatic cell count herds
5. The problem of immunisation against staphylococcal mastitis
6. Antiphagocytic effect of the capsule of Streptococcus uberis
7. Virulence factors of Streptococcus uberis isolated from cows with mastitis
8. Isolation and characterisation of hyaluronidase from Streptococcus uberis
9. Purification of a plasminogen activator from Streptococcus uberis
10. A novel plasminogen activator from Streptococcus uberis
11. Identification of lactoferrin-binding proteins in bovine mastitis-causing Streptococcus uberis
12. Partial characterization of the cohemolytic factor produced by Streptococcus uberis and comparison with the CAMP-factor
13. Cloning, sequencing and expression of the CAMP factor gene of Streptococcus uberis
14. Unspecific binding of group B streptococcal cocytolysin (CAMP-factor) to immunoglobulins and its possible role in pathogenicity
15. Cloning, sequence analysis, and expression in E. coli of a streptococcal plasma receptor
16. A major surface protein on group A streptococci is a glyceraldehyde-3-phosphate-dehydrogenase with multiple binding activity
17. Glyceraldehyde-3-phosphate dehydrogenase on the surface of group A streptococci is also an ADP-ribosylating enzyme
18. Immune modification of the pathogenesis of Streptococcus uberis mastitis in the dairy cow
19. Further studies on the efficacy of a live vaccine against mastitis caused by Streptococcus uberis
20. Local vaccination with killed Streptococcus uberis protects the bovine mammary gland against experimental intramammary challenge with the homologous strain
21. Vaccination with the plasminogen activator from Streptococcus uberis induces an inhibitory response and protects against experimental infection in the dairy cow
22. Molecular characterization of the cfb gene encoding group B streptococcal CAMP-factor
23. Protection of cattle from BHV-1 infection by immunization with recombinant glycoprotein gIV
24. New insights into an old protein: The functional diversity of mammalian glyceraldehyde-3-phosphate dehydrogenase
25. Human resistance to Schistosoma mansoni is associated with IgG reactivity to a 37-kDa larval surface antigen
26. Identification of a candidate vaccine peptide on the 37 kDa Schistosoma mansoni GAPDH
27. Production of Sm37-GAPDH, a major therapeutical target in human schistosomiasis
28. The rational design of trypanocidal drugs: Selective inhibition of the glyceraldehyde-3-phosphate dehydrogenase in Trypanosomatidae
29. Detrimental effect of nitric oxide on Trypanosoma cruzi and Leishmania major like cells